Sequana Medical AG Raises CHF 9 million (USD 9.3M) in a Series C Extension

23. October 2015

Transaction Includes New Investors Salus Partners and Quest for Growth

Sequana Medical AG, a privately held medical device company focused on the development and commercialization of innovative implantable pump systems that manage excess fluid within the body, announced today that it has raised CHF 9 million ($9.3 million) in a Series C extension round.  Existing investors including NeoMed Management AS, VI Partners AG, Biomed Invest AG, Capricorn Health-tech Fund, Entrepreneurs Fund and Life Science Partners participated for a total of CHF 5.3M, with a further CHF 3.7M raised from new investors including Salus Partners SA and Quest for Growth NV.  Sequana Medical will use these funds to expand current business for its proven fluid management systems through new indications in heart disease and to pursue U.S. marketing approvals.

Read more

Sequana Medical presented the alfapump® system at this year’s Viszeralmedizin Congress in Leipzig, Germany

13. October 2015

Sequana Medical was delighted to present the alfapump system for the third time at this year’s nationwide Viszeralmedizin Congress, organised by the DGVS (German Society for Gastroenterology, Digestive and Metabolic Diseases) and the DGAV (German Society for General and Visceral Surgery), held in Leipzig’s CCL Congress Centre.

Read more

Sequana Medical signs collaboration agreement with Fresenius Medical Care for the marketing and distribution of the alfapump® system.

16. April 2015

Sequana Medical, a Swiss-based medical device company, announced today that it has entered into an agreement with Fresenius Medical Care to commercialize its innovative alfapump system.

Read more

Sequana Medical presents exciting clinical updates on the alfapump® System at this year’s International Liver Congress in Vienna.

13. April 2015

Sequana Medical is delighted to be attending this year’s International Liver Congress in Vienna to present alfapump with DirectLink Technology.

Read more

Sequana Medical appoints Medinistros SAS as distributor for the alfapump® system in Colombia

27. March 2015

Sequana Medical is pleased to announce the appointment of Medinistros SAS as exclusive distributor for the alfapump system in Colombia.

Read more

Sequana Medical supports Bristol hepatologist Dr Anne McCune’s Sahara Challenge in aid of the British Liver Trust

10. March 2015

Sequana Medical is proud to support Dr Anne McCune in her brave trek across the Sahara in aid of the British Liver Trust.

Read more

Sequana Medical’s new alfapump® with DirectLink Technology improves the care of patients with challenging refractory ascites

01. December 2014

Technological advances in Sequana Medical’s alfapump system will allow patients and their doctors to better manage the distressing symptoms of refractory ascites. With enhanced communications enabled by the new DirectLink Technology, clinicians will now be able to monitor the alfapump remotely.

Read more

alfapump® at the International Liver Congress 2014 in London

09. April 2014

Sequana Medical is delighted to be attending this year’s International Liver Congress in London.

Read more

HUG Geneva adds the alfapump® system to its range of treatments for refractory ascites

24. February 2014

Sequana Medical is delighted to report that HUG, the university hospital of Geneva, is now offering the alfapump system as a treatment option for patients suffering from refractory ascites.

Read more

Britain’s ‘Sun’ newspaper reports that the alfapump® system gives hope to liver patients

07. January 2014

The alfapump system featured once again in the British press, this time in the ‘Sun’ newspaper.

Read more